Posdinemab  (Synonyms: JNJ-63733657)

Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

MAPT

人工脑脊液及小鼠脑匀浆实验^[2]：
Posdinemab (100 nM；免疫沉淀孵育过夜+酶解 20 h) 特异性结合磷酸化 tau (p217+tau)，通过免疫沉淀富集目标肽段，检测到含 pT217 位点的双磷酸化 tau 肽 SRTPSLPTPPTREPK?2p，证实抗体对磷酸化 tau 的高亲和力及选择性捕获能力^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1. Posdinemab (1-60 mg/kg；单次；静脉注射) 显示良好安全性和耐受性，血清药代动力学呈线性，脑脊液 (CSF) 中游离及总 p217+tau 水平呈剂量依赖性下降^[1]。
2. Posdinemab 可用于检测 CSF 中双磷酸化 tau 肽 SRTPSLPTPPTREPK?2p (含 pT217 位点) ，且处理后的总p217+tau水平下降^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

4137  [NCBI]

P10636

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.331 kDa

2517973-04-3

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Galpern WR, et al. Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis. 2024;11(6):1592-1603.  [Content Brief]

  [2]. Bijttebier S, et al. Development of immunoprecipitation - two-dimensional liquid chromatography-mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients. J Chromatogr A. 2021 Aug 16;1651:462299.  [Content Brief]

  [3]. Panza F, et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):625-634.  [Content Brief]